|
 |
|
|||||||
|
|||||||||
Statements of interest
The following authors have declared a statement of interest concerning papers published in volume 34 of the ERJ.
Statements of interest from previous volumes may be viewed here: volume 33; volume 32; volume 31; volume 30; volume 29.
A
Back to Top
M.J. Abramson served on the scientific advisory committee for the Australian Asthma Study, which was sponsored by GlaxoSmithKline, and has once received travel assistance for conference attendance from AstraZeneca and a speaker’s honorarium from Boehringer Ingelheim. He is a co-investigator on a Reckitt-Benckiser-supported study of nonsteroidal anti-inflammatory drugs in asthma. DOI: 10.1183/09031936.00181608
G. Acuto has acted as an expert witness on the study topic. The author’s study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
M. Adner. The author’s study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
S. Aldington. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
N. Ambrosino. Vivisol funded an annual position at University Hospital of Pisa for one member of staff. DOI: 10.1183/09031936.00182208
J.A. Anderson is employed by and holds shares in GlaxoSmithKline. The author's study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
J.A. Anderson is employed by and holds shares in GSK. DOI: 10.1183/09031936.00122608
J.M. Antó is principal investigator of a project that, in addition to competitive external multi-source funding, has been contributed to by AstraZeneca (€60,000 in 2008). DOI: 10.1183/09031936.00172908
J.G. Ayres was supported by a non-commercial grant from Talecris Biotherapeutics who had no involvement in study design or conduct, manuscript preparation or submission. DOI: 10.1183/09031936.00087908
B
Back to Top
P.S. Bakke. This study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of whom market treatments for chronic obstructive pulmonary disease (COPD). DOI: 10.1183/09031936.00190908
B. Bausch. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. This grant paid for consumables and the salary of B. Bausch. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author’s systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
B. Bausch. The author’s work did not have specific funding, and was done in time made available by the authors’ institutes. However, the study partly used data available from previous work. With relation to this previous work, the Horten Centre received a grant from Kleijnen Systematic Reviews Ltd for conducting systematic reviews in respiratory medicine. This grant paid for consumables and the salaries of B. Bausch and A. Spaar. DOI: 10.1183/09031936.00159108
R. Beasley has received fees for consulting and speaking and reimbursement for attending symposia from AstraZeneca, GlaxoSmithKline and Novartis. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00159708
R. Beasley. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. R Beasley has received fees for consulting and speaking and reimbursement for attending symposia from AstraZeneca, GlaxoSmithKline and Novartis. The present study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
M-F. Beauchesne has received grant support from AstraZeneca Canada Inc and GlaxoSmithKline Canada Inc for the conduct of her research projects. She has also received consulting fees from GlaxoSmithKline Canada Inc and speaking fees from GlaxoSmithKline Canada Inc, Boehringer Ingelheim Canada Inc., AstraZeneca Inc, and Pfizer Canada Inc. She co-chairs the AstraZeneca Endowment Pharmaceutical Chair in Respiratory Health. DOI: 10.1183/09031936.00074608
P. Berry was employed by GlaxoSmithKline at the time of the study. The present study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
L. Blais has carried out research contracts for AstraZeneca (Canada and USA) and Amgen Canada Inc., and co-chairs the AstraZeneca Endowment Pharmaceutical Chair in Respiratory Health. DOI: 10.1183/09031936.00074608
The BOLD study. Funding for the BOLD Operations Center was provided by unrestricted educational grants from ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough, Sepracor and University of Kentucky. The Reykjavik BOLD site was funded by the Landspitali University Science Fund, Astra Zeneca in Iceland and GlaxoSmithKline in Iceland. The Norwegian BOLD site was funded by the Research Fund for Respiratory Medicine, Haukeland University Hospital and The Norwegian Association of Heart and Lung Patients and EXTRA funds from the Norwegian Foundation for Health and Rehabilitation. DOI: 10.1183/09031936.00166108
A.L. Boner travel to ERS congress was funded by GSK, he received fees for speaking from GSK and MSD, a research found of &euros;5,000 from Pfizer, and he served once as a consultant in two international meetings, one organised by GSK and one by MSD. DOI: 10.1183/09031936.00166508
L. Bont received €12,000 from Abbott International for lectures and participation in Advisory Boards. DOI: 10.1183/09031936.00166508
A. Boonstra has acted as a paid speaker for Actelion and United Therapeutics. A. Boonstra has attended symposia funded by Encysive, Pfizer and Actelion. The employer of A. Boonstra has received an unrestricted educational grant from Actelion and GlaxoSmithKline in the past 5 years exceeding €10,000. DOI: 10.1183/09031936.00106008
E.K.Borton has been partially funded via grants from ConAgra through the University of Cincinnati College of Medicine for his involvement in the medical surveillance program. E.K. Borton has received funding from ConAgra for conduction medical surveillance. The author’s study was supported by ConAgra. DOI: 10.1183/09031936.00050808
W.J. Boscardin. The author’s study was funded by Eumedic, Ltd. DOI: 10.1183/09031936.00037409
O. Braendli. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. This grant paid for consumables. O. Braendli did not receive any salary support for his contribution to the paper. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author’s systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
P. Brand was an employee of Inamed Research when the study was conducted. The study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
V. Brusasco received €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €3,000 in 2004, €3,000 in 2005 and €3,500 from Lofarma for consultancies; €3,750 in 2004 from MSD for consultancy; €6,000 in 2004, €11,500 in 2005, €8,325 in 2006, €2,500 in 2007 and €6,600 for speaking at conferences sponsored by Boehringer Ingelheim; £960 in 2006 and £1,200 in 2008 from GSK for participating in advisory boards; €6,000 in 2006 and €3000 in 2007 from Almirall for serving on an advisory board; €3,000 in 2006 from Forest Laboratories for serving in an advisory board; €1,500 from Menarini for consusltancy. V. Brusasco’s institution received €20,000 in 2006 from Boehringer Ingelheim as an unrestricted research grant, and participated in several multicentre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK, Novartis). DOI: 10.1183/09031936.00103309
V. Brusasco received €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €3,000 in 2004, €3000 in 2005 and €3,500 from Lofarma for consultancies; €3,750 in 2004 from MSD for consultancy; €6,000 in 2004, €11,500 in 2005, €8,325 in 2006, €2,500 in 2007 and €6,600 for speaking at conferences sponsored by Boehringer Ingelheim; £960 in 2006 and £1,200 in 2008 from GSK for participating in advisory boards; €6,000 in 2006 and €3,000 in 2007 from Almirall for serving in an advisory board; €3,000 in 2006 from Forest Laboratories for serving in an advisory board; €1,500 from Menarini for consultancy. V. Brusasco’s institution received €20,000 in 2006 as unrestricted research grant from Boehringer Ingelheim, and participated in several multicentre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK and Novartis). DOI: 10.1183/09031936.00061509
V. Brusasco received: €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €3,000 in 2004, €3,000 in 2005 and €3,500 from Lofarma for consultancies; €3,750 in 2004 from MSD for consultancy; €6,000 in 2004, €11,500 in 2005, €8,325 in 2006, €2,500 in 2007 and €6,600 for speaking at conferences sponsored by Boehringer Ingelheim; £960 in 2006 and £1,200 in 2008 from GSK for participating in advisory boards; €6,000 in 2006 and €3,000 in 2007 from Almirall for serving in an advisory board; €3,000 in 2006 from Forest Laboratories for serving in an advisory board; €1,500 from Menarini for consusltancy. VB’s institution received €20,000 in 2006 as an unrestricted research grant from Boehringer Ingelheim, and participated in several multicentre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK, Novartis). DOI: 10.1183/09031936.00074809
G. G. Brusselle received lecture fees and honoraria for serving on advisory boards from Astra Zeneca, Boehringer Ingelheim, Glaxo Smith Kline, Pfizer, Novartis and UCB in 2004-2008. DOI: 10.1183/09031936.00150208
P.S. Burge funds, distributes and supports the Oasys-2 program for analysing serial PEF measurements for no financial gain to himself or his department. DOI: 10.1183/09031936.00150108
A. Bush has been received expenses to travel to the American Thoracic Society from GSK, MSD and Altana, and speakers fees from MSD and GSK; he has received a grant for a study of inhaled mannitol in cystic fibrosis from Pharmaxis, Australia. DOI: 10.1183/09031936.00166508
C
Back to Top
P.M.A. Calverley has spoken at meetings supported by GlaxoSmithKline, AstraZeneca and Chiesi. He has advised on trial design and research strategy for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche, Nycomed, Almirall and Pfizer. His department has received research funding from GlaxoSmithKline, Altana and Chiesi to conduct clinical trials and observational research in COPD. He has also received fees for consulting. This study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
P.M.A. Calverley has spoken at meetings supported by GSK, AstraZeneca and Chiesi. He has advised on trial design and research strategy for AstraZeneca, Boehringer Ingeheim, GSK, Roche, Nycomed, Almirral and Pfizer. His department has received research funding from GSK, Altana and Chiesi to conduct clinical trials and observational research in COPD. DOI: 10.1183/09031936.00122608
P. Calverley has received fees for consulting, a fee for speaking and funds for research. P. Calverley has spoken at meetings supported by GSK, AstraZeneca, Boehringer Ingelheim and Nycomed. He has also received research funding to conduct clinical trials for these companies and has advised them and Novartis, Roche and Chiesi on clinical trail design. DOI: 10.1183/09031936.00022809
K-H. Carlsen has received reimbursement for attending American Thoracic Society Annual Congress 2005 and 2006 from GlaxoSmithKline and American Academy of Asthma, Allergy and Immunology Annual Congress 2007 and 2008 from MSD, also received fees for speaking from GlaxoSmithKleine, MSD and Astra Zeneca. DOI: 10.1183/09031936.00166508
M. Cazzola has received honoraria for speaking and consulting and/or financial support for attending meetings from Abbott, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dey, GlaxoSmithKline, Kerios, Menarini Farmaceutici, Novartis, Nycomed (former Altana), Pfizer, Sanovel, Sigma Tau and Valeas, and is a member of the speaker bureau of Novartis. DOI: 10.1183/09031936.00013109
B. Celli has been reimbursed by GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Almirall for participating in advisory boards and speaking at different meetings. The Division he heads has been awarded research grants for different medication trials and for the discovery of new biomarkers in COPD. This study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
B.R. Celli has been reimbursed by GSK, BI, AZ and Almirall for participating in advisory boards and spoken at different meetings. The Division he heads has been awarded research grants for different medication trials and for the discovery of new biomarkers in COPD. DOI: 10.1183/09031936.00122608
H. Chen has been a consultant for EpiMetrix, Genentech, Gilead Science, Nektar Therapeutics, Novartis Pharmaceuticals, and United Therapeutics. DOI: 10.1183/09031936.00083909
W-H. Chen was employed by United BioSource Corporation at the time of the study. The present study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
H.R. Collard has been a consultant for Actelion, Amira Pharmaceuticals, CV Therapeutics, Genzyme, Gilead Science, InterMune, Nektar Therapeutics, and Roche. DOI: 10.1183/09031936.00083909
J.R. Colthurst. The present study was funded by Eumedic, Ltd. J.R. Colthurst designed the Fenzian treatment system and founded Eumedic Ltd in which he has a shareholding. J.R. Colthurst works at Eumedic Ltd. DOI: 10.1183/09031936.00037409
C.B. Cooper. The present study was funded by Eumedic, Ltd. C.B. Cooper received financial support from Eumedic to attend an ATS annual meeting where an abstract relating to this study was presented and an investigator meeting held. C.B. Cooper has received an additional grant for a multi-centre clinical trial of the Fenzian device from Eumedic, Ltd. DOI: 10.1183/09031936.00037409
H.O. Coxson received $4800 in 2006 and 2007 for serving on the steering committee for the ECLIPSE project for GlaxoSmithKline. In addition, H.O. Coxson is the co-investigator on two multicenter studies sponsored by GlaxoSmithKline and has received travel expenses to attend meetings related to the project. He has three contract service agreements with GlaxoSmithKline to quantify the CT scans in subjects with COPD and a service agreement with Spiration Inc. to measure changes in lung volume in subjects with severe emphysema. A percentage of H.O. Coxson’s salary between 2003 and 2006 (US$15,000 per year) derives from contract funds provided to a colleague, P.D. Pare, by GlaxoSmithKline for the development of validated methods to measure emphysema and airway disease using computed tomography. H.O. Coxson is the co-investigator (D. Sin Principal Investigator) on a Canadian Institutes of Health – Industry (Wyeth) partnership grant. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
H. Coxson received US$4,800 in 2006 and 2007 for serving on the steering committee for the ECLIPSE project for GSK. In addition HC is the co-investigator on two multi-centre studies sponsored by GSK and has received travel expenses to attend meetings related to the project. HC has three contract service agreements with GSK to quantify the CT scans in subjects with COPD and a service agreement with Spiration Inc to measure changes in lung volume in subjects with severe emphysema. A percentage of HC’s salary between 2003 and 2006 (US$15,000/year) derives from contract funds provided to a colleague Peter D Pare by GSK for the development of validated methods to measure emphysema and airway disease using computed tomography. HC is the co-investigator (D Sin PI) on a Canadian Institutes of Health – Industry (Wyeth) partnership grant. DOI: 10.1183/09031936.00141808
C. Crim is an employee of GlaxoSmithKline, which sponsored the TORCH trial. This study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
D
Back to Top
S-E. Dahlén. The author’s study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
F.M. de Benedictis has received research support and consulting fees, and has given lectures for Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp Dohme, UCB. DOI: 10.1183/09031936.00166508
C. de la Roza is an employee of Bayer Schering Pharma, the company sponsoring the study and manufacturing moxifloxacin. DOI: 10.1183/09031936.00195608
C. Delclaux has received a free NO analyser (price €30 000) from SERES Company for the development of the software dedicated to the multiple constant flow method. DOI: 10.1183/09031936.00164508
A. De Luisi has acted as an expert witness on the study topic. The author’s study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
G. Deslee received grants for post-doctoral training from AstraZeneca (Paris, France). DOI: 10.1183/09031936.00123008
H.J. Dettmar is an employee of Technostics Ltd. DOI: 10.1183/09031936.00126908
P.W. Dettmar is a director of Selfnostics Ltd, which holds the rights to Cough Clinic, and is an employee of Technostics Ltd. DOI: 10.1183/09031936.00126908
A. Dirksen. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
E
Back to Top
L.D. Edwards is an employee of GlaxoSmithKline. The author’s study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
G.E. Eide. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
P.L. Enright has received a total of about $25,000 from Pfizer during the period 2006–2008 for reviewing the quality of spirometry tests in a study of the effectiveness of varenicline for smoking cessation in patients with COPD. Pfizer and Boehringer co-market tiotropium for COPD, so increasing the spirometry abnormality rates amongst smokers would increase their profits. DOI: 10.1183/09031936.00164608
C. Esquinas. The author’s study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
R. Ewert has received speaker fees from Bayer/Schering, Actelion and Encysive/Pfizer. DOI: 10.1183/09031936.00130408
F
Back to Top
G.T. Ferguson has received consulting fees from Boehringer-Ingelheim, GlaxoSmithKline, Novartis and Schering Plough; speaking fees from Boehringer-Ingelheim, GlaxoSmithKline and Pfizer; and grant support from Altana, Boehringer-Ingelheim, Emphasys Medical Inc, Forrest, GlaxoSmithKline, Mannkind Corporation and Novartis. DOI: 10.1183/09031936.00122608
G.T. Ferguson has received consulting fees from Boehringer-Ingelheim, GlaxoSmithKline, Novartis and Schering Plough; speaking fees from Boehringer-Ingelheim, GlaxoSmithKline and Pfizer; and grant support from Altana, Boehringer-Ingelheim, Emphasys Medical Inc, Forrest, GlaxoSmithKline, Mannkind Corporation and Novartis. This study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
A. Ferland. The author’s study was supported by Abbott Pharmaceutical. DOI: 10.1183/09031936.00167308
B. Fleury is joint owner of a French patent for a hydraulic oral appliance titration system that is not marketed. DOI: 10.1183/09031936.00148208
G
Back to Top
S.P. Gaine has received speaker’s honoraria and research support from companies involved in pulmonary arterial hypertension including Actelion, GSK, Pfizer/Encysive, and Lung Rx. DOI: 10.1183/09031936.00058408
M. García. The author’s study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
H. A. Ghofrani has received lecturer honoraria from Actelion Pharmaceuticals, Bayer/Schering, GSK, Pfizer and Encysive. He is also a member of scientific advisory boards for Actelion Pharmaceuticals, Bayer, Encysive/Pfizer, GSK and LungRx. DOI: 10.1183/09031936.00130408
K.I. Gourgoulianis has received an unrestricted grant from Pfizer Greece. (Daenas C, Hatziefthimiou AA, Gourgoulianis KI, Molyvdas PA. Azithromycin has a direct relaxant effect on precontracted airway smooth muscle. Eur J Pharmacol 2006; 553:280-287.) DOI: 10.1183/09031936.00089407
A. Greenough has received education grants from Abbott Laboratories Ltd, research funds from Abbott Laboratories Ltd and MedImmune and fees for lecturing/chairing meetings from Abbott Laboratories Ltd. DOI: 10.1183/09031936.00166508
M. Griese has received one fee for speaking from Bayer Heath Care and a fee for consulting from CLS Behring. DOI: 10.1183/09031936.00029809
T.B. Grydeland. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
A. Gulsvik. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
H
Back to Top
M. Halank has received lecturer honoraria from Actelion Pharmaceuticals and Bayer/Schering. DOI: 10.1183/09031936.00175208
A. Hamilton. The author’s study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
K. Hanna is an employee of Talecris Biotherapeutics. The author’s study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
G. Harding is employed by the United BioSource Corporation, which provides consulting and other research services to pharmaceutical, device, government and nongovernment organisations. In this salaried position, G. Harding works with a variety of companies and organisations and receives no payment or honoraria directly from these organisations for services rendered. The present study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
R.M. Harrison was supported by a non-commercial grant from Talecris Biotherapeutics who had no involvement in study design or conduct, manuscript preparation or submission. DOI: 10.1183/09031936.00087908
M. Harwood. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00159708
A.A. Hatziefthimiou has received an unrestricted grant from Pfizer Greece. (Daenas C, Hatziefthimiou AA, Gourgoulianis KI, Molyvdas PA. Azithromycin has a direct relaxant effect on precontracted airway smooth muscle. Eur J Pharmacol 2006; 553:280-287.) DOI: 10.1183/09031936.00089407
Z. He. The author’s study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
D. Heederik received grants from the Produktschap Granen, Zaden en Peulvruchten, Den Haag, The Netherlands, for development and conduct and analysis of a surveillance system of occupational allergy and asthma in flour processing and bakery products industries of approx. 450000 euro. DOI: 10.1183/09031936.00164408
C.H. Herpich is an employee of Inamed Research. The author’s study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
R. Hervás. The author’s study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
T.J. Hilbert has been partially funded via grants from ConAgra through the University of Cincinnati College of Medicine for his involvement in the medical surveillance programme. T.J. Hillbert has received funding as a consultant to ConAgra, for the presentation of preliminary results of the medical surveillance program to various United States Federal agencies, and for conducting medical surveillance. The author’s study was supported by ConAgra. DOI: 10.1183/09031936.00050808
J. Hjoberg. The author’s study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
M.M. Hoeper has speaker and consultant fees from Actelion, Bayer, Encysive, GSK, Lilly, LungRx, Novartis, and Pfizer. DOI: 10.1183/09031936.00056809
M.M. Hoeper has received speaking and/or consulting fees from Actelion, Bayer, Encysive, Gilead, GSK, Lilly, LungRx, Novartis and Pfizer. DOI: 10.1183/09031936.00094409
M.M. Hoeper has received lecturer honoraria from Actelion Pharmaceuticals, Bayer/Schering, GSK, Pfizer and Encysive. The author is also a member of scientific advisory boards for Actelion Pharmaceuticals, Bayer, Encysive/Pfizer, GSK and LungRx. DOI: 10.1183/09031936.00013309
M. M. Hoeper has received lecturer honorariums from Actelion Pharmaceuticals, Bayer/Schering, GSK, Pfizer and Encysive. He is also a member of scientific advisory boards for Actelion Pharmaceuticals, Bayer, Encysive/Pfizer, GSK and LungRx. DOI: 10.1183/09031936.00130408
D.H. Horstman is an employee of GlaxoSmithKline. The author’s study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
M. Humbert has relationships with drug companies including Actelion, BayerSchering, GlaxoSmithKline, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and memberhip of scientific advisory boards. DOI: 10.1183/09031936.00006508
M. Humbert has, in the past 5 years, received: reimbursement for attending a symposium; fees for speaking; fees for organising education; funds for research; funds for a member of staff; fees for consulting. M. Humbert has relationships with drug companies including Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00102609
I
Back to Top
J
Back to Top
C. Jenkins has received fees for organising and speaking at educational symposia sponsored by GlaxoSmithKline; his institute receives predominantly project-based, but some untied funding for research. DOI: 10.1183/09031936.00122608
C. Jenkins has received fees for organising and speaking at educational symposia sponsored by GlaxoSmithKline; her institute receives predominantly project based, but some untied funding for research. The author’s study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
S. Jonasson. The author’s study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
P.W. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings and has received support for research from GlaxoSmithKline. The author’s study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
P.W. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings, and received support for research from pharmaceutical companies, including GlaxoSmithKline. The author’s study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
P.W. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings and received support for research from pharmaceutical companies, including GlaxoSmithKline. DOI: 10.1183/09031936.00122608
M. Jung has given a lecture at Merck and Co in 2006 for which a single fee was received. DOI: 10.1183/09031936.00084808
E.F. Juniper has, in the past 5 years, received fees for speaking, funds for research and fees for consulting. Consultant arrangements: GlaxoSmithKline, Astra Zeneca. Stock/other equity ownership: GlaxoSmithKline, Pfizer. Patent licensing arrangements: Copyright holder of the ACQ. Financial support (last 5 years): Johnson & Johnson, Schering Plough, Medpointe Pharma, CMP Therapeutics, Alterhealth, Pierre Fabre, GlaxoSmithKline, Munipharma, Ception Therapeutics, Sunten Phytotech, UCB Pharma, Activus Pharma, Novartis, Wyeth, Allergopharma, Airsonett, Embria Health Sciences, CV Technologies, Kalobios, Stallergens, AstraZeneca, Alk Abello, Medicinova, Artu Biologicals, Curalogic, IFE Europe, Genentech, Epigenesis, Merck, Cipla, Amgen, Rottapharma, Allergy Therapeutics, NovoNordisk, Inflazyme, Allergy Choices, Abbott Laboratories, Mitsubishi, Boehringher Ingelheim, Cytos Technologies, Wellpoint/Healthcore, Altanapharma, Capnia, Ivax Laboratories, Critical Therapeutics, Kyowa Hakko, Asthmatx, Neolab, Protein Design Laboratories, ClinPhone, Arriva, Schulman Ronca Bucuvals, Laboratories SMB, Vista Health Plan, Hal Allergy BV, Suburban Lung Associates, Galephar MF SA, Mannkind Corp, Prognostix, Formix Biosciences, Oxagen, SC Ellen Fast Comimpex SRL, Medimmune, Quintiles, PDL Biopharma, Bencard, Efficas, Pfizer, Alcon Lab, Aventis, Pahrmaxis, Assist Tech, Hoffmann LaRoche, Aerocrine, Dynavax, Medtap, Pharmaengine, Topigen, ClineDavis & Mann, Teikoku Pharma, NeoLab, KGK Synergise, AB Science.
K
Back to Top
O.N. Keene is a full-time employee of GlaxoSmithKline and holds shares in the company. DOI: 10.1183/09031936.00122608
S. Kesten. This study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
J. Kimpen received speakers fees over the years 2004-2006 from Abbott International for a total amount of €20,000. DOI: 10.1183/09031936.00166508
E.C. Kleerup. The author’s study was funded by Eumedic, Ltd. E.C. Kleerup has received an additional grant for a multi-centre clinical trial of the Fenzian device from Eumedic, Ltd. DOI: 10.1183/09031936.00037409
J. Kleijnen. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author’s systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
J. Kleijnen. The author’s work did not have specific funding, and was done in time made available by the authors’ institutes. However, the study partly used data available from previous work. With relation to this previous work, the Horten Centre received a grant from Kleijnen Systematic Reviews Ltd for conducting systematic reviews in respiratory medicine. This grant paid for consumables and the salaries of B. Bausch and A. Spaar. J. Kleijnen is an employee of Kleijnen Systematic Reviews Ltd. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the analyses or the writing of this article. DOI: 10.1183/09031936.00159108
G. Klein is an employee of Talecris Biotherapeutics The study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
N. Kline Leidy is employed by, and holds stocks/shares in, the United BioSource Corporation, which provides consulting and other research services to pharmaceutical, device, government and nongovernment organisations. In this salaried position, N. Kline Leidy works with a variety of companies and organisations and receives no payment or honoraria directly from these organisations for services rendered. The present study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
L
Back to Top
T. Lahm has received a research grant from Pfizer, Inc ($16,800) to investigate the effects of sitaxsentan on pulmonary artery vasoreactivity in an animal model of endotoxinemia. This is not in relation to the topic of the current manuscript. DOI: 10.1183/09031936.00038909
Y-M. Lam. This study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
K. Larsson. The author’s study was supported by a grant from the Research Department of AFA Insurance Company (Stockholm, Sweden). DOI: 10.1183/09031936.00105308
T. A. Lee has received research funding for his contribution to the Burden of Obstructive Lung Disease (BOLD) Initiative, which has been funded in part by unrestricted educational grants to the Operations Center (www.boldcopd.org) from ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough, Sepracor and University of Kentucky and has received past research grants from AstraZeneca, Boehringer-Ingelheim, Pfizer and GlaxoSmithKline and has participated in past advisory boards for AstraZeneca and Novartis. DOI: 10.1183/09031936.00166108
G.K. LeMasters. The author’s study was supported by ConAgra. DOI: 10.1183/09031936.00050808
W. Lenney has received speaker fees from GSK and Novartis and has received educational grants for research projects from Abbott Laboratories and GSK. DOI: 10.1183/09031936.00166508
L.P. Levin. The author’s study was supported by ConAgra. DOI: 10.1183/09031936.00050808
N.W. Locantore is an employee of GlaxoSmithKline. The author’s study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
J.E. Lockey has received funding as a consultant to ConAgra and for the presentation of preliminary results of the medical surveillance programme to various United States Federal agencies. J. Lockey has received grants from ConAgra through the University of Cincinnati College of Medicine for directing and analysing the data of the medical surveillance programme and for salary support of contributing faculty and support staff. The author’s study was supported by ConAgra. DOI: 10.1183/09031936.00050808
D.A. Lomas has received an educational grant and fees for speaking and acts as a consultant for GlaxoSmithKline. The present study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
M
Back to Top
H. Magnussen received fees for speaking from Boehringer Ingelheim and funds for research from Boehringer Ingelheim. This study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
F. Maltais has received research funding support from BI/Pfizer, GSK and Novartis; and has served on speakers bureaus, consultation panels and advisory boards for GSK and BI/Pfizer. This study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
G. Mangialardi has acted as an expert witness on the study topic. The author’s study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
A. Marín. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
S.E. Marsh. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
C. Martínez has received fees for organising education and consulting, and funds for research and a member of staff. DOI: 10.1183/09031936.00180708
M.G. Matera has received honoraria for consulting and/or financial support for attending meetings from Nycomed (former Altana), AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Pfizer. DOI: 10.1183/09031936.00013109
R.T. McKay was partially funded by ConAgra Foods for the design of a pulmonary surveillance and spirometry quality assurance programme. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
T. Meyer works for a contract research organisation that conducted the study on behalf of Talecris. The study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
L. Millares. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
B.E. Miller is an employee of GlaxoSmithKline. The author’s study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
M. Miravitlles has received honoraria for lecturing from Bayer Schering Pharma and is member of the advisory board of the company. The current study was funded by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
T.J. Mitchell has received funding for research from Wyeth Vacccines and GlaxoSmithKline Biologicals. DOI: 10.1183/09031936.00007109
P-A. Molyvdas has received an unrestricted grant from Pfizer Greece. (Daenas C, Hatziefthimiou AA, Gourgoulianis KI, Molyvdas PA. Azithromycin has a direct relaxant effect on precontracted airway smooth muscle. Eur J Pharmacol 2006; 553:280-287.) DOI: 10.1183/09031936.00089407
E. Monsó has received research funding from Bayer Healthcare for participating in clinical trials promoted by the company. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
J. Morera has received research funding from Bayer Healthcare for participating in clinical trials promoted by the company. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
A.H. Morice is a director of Selfnostics Ltd, which holds the rights to Cough Clinic. DOI: 10.1183/09031936.00126908
N
Back to Top
R. Naeije has received reimbursements of travel expenses to congresses and speakers’ fees from Actelion, Encysive, Pfizer, Glaxo, Bayer, LungRX and Mondobiotech, and funds for research from Actelion and Encysive. DOI: 10.1183/09031936.00107108
T. Neimert-Andersson. The author’s study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
M.R. Nowitz. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
O
Back to Top
D.E. O’Donnell has received research funding support from BI/Pfizer, GSK, Merck and Novartis; and has served on speakers bureaus, consultation panels and advisory boards for GSK and BI/Pfizer. The author’s study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
K. Olsson has received speaker fees from Bayer/Schering. DOI: 10.1183/09031936.00130408
M. Olsson. This study was supported by a grant from the Research Department of AFA Insurance Company (Stockholm, Sweden). DOI: 10.1183/09031936.00105308
C. Opitz has received lecture fees / honoraria from Actelion, Bayer Schering, Encysive/Pfizer and GlaxoSmithKline. DOI: 10.1183/09031936.00145708
C. Opitz has received speaker fees from Bayer/Schering, Actelion and Encysive/Pfizer. DOI: 10.1183/09031936.00130408
P
Back to Top
L. Palmberg. This study was supported by a grant from the Research Department of AFA Insurance Company (Stockholm, Sweden). DOI: 10.1183/09031936.00105308
D.N.R. Payne has received lecture fees and consultancy fees from AstraZeneca and Kyorin pharmaceuticals and has received financial assistance for travel and accommodation from Kyorin pharmaceuticals. DOI: 10.1183/09031936.00186508
A. Peacock has received funds for travelling to meetings, consultancy work and attending advisory boards for Actelion, Pfizer, GlaxoSmithKline, Encysive, Eli Lilly and United Therapeutics. DOI: 10.1183/09031936.00107108
K. Perrin. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00159708
B. Pételle. is joint owner of a French patent for a hydraulic oral appliance titration system that is not marketed. DOI: 10.1183/09031936.00148208
S.G. Pillai is an employee of GlaxsoSmithKline. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
S.G. Pillai is a full-time employee of GlaxoSmithKline. DOI: 10.1183/09031936.00141808
P. Poirier. The author’s study was supported by Abbott Pharmaceutical. DOI: 10.1183/09031936.00167308
D.S. Postma is a member of an Advisory Board at GlaxoSmithkline, Boehringer Ingelhem and TEVA. She has received honoraria from Astra Zeneca and Nycomed and has received an Industry-Sponsored grant from Astra Zeneca, GalaxoSmithKline and Nycomed. DOI: 10.1183/09031936.00022809
S. Provencher has received lecture fees from Actelion Pharmaceuticals Canada Inc, Encysive Canada Inc and received consultant fees from Actelion Pharmaceuticals Canada Inc, Encysive Canada Inc, GlaxoSmithKline Canada Inc and Pfizer Canada Inc. DOI: 10.1183/09031936.00068009
M.A. Puhan. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. M.A. Puhan did not receive any salary support but put his honorarium into the general research account of the Horten Centre to support academic activities of the Centre. M.A. Puhan is supported by a career award of the Swiss National Science Foundation (3233B0/115216/1). Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author’s systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
M.A. Puhan has received no personal payments from pharmaceutical industry, but has received unrestricted grants for investigator-initiated research that were deposited into research accounts of the research groups that he belongs to from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca for development of quality-of-life instruments and respiratory rehabilitation trials. DOI: 10.1183/09031936.00095408
M.A. Puhan. The author’s work did not have specific funding, and was done in time made available by the authors’ institutes. However, the study partly used data available from previous work. With relation to this previous work, the Horten Centre received a grant from Kleijnen Systematic Reviews Ltd for conducting systematic reviews in respiratory medicine. This grant paid for consumables and the salaries of B. Bausch and A. Spaar. M.A. Puhan did not receive any salary support but put his honorarium into the general research account of the Horten Centre to support academic activities of the Centre. DOI: 10.1183/09031936.00159108
Q
Back to Top
R
Back to Top
S.E. Rees is a board member and shareholder of OBI APS. OBI APS is currently applying for a patent on the method presented in this manuscript. DOI: 10.1183/09031936.00105909
R. Ria has acted as an expert witness on the study topic. The present study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
D. Ribatti has acted as an expert witness on the study topic. The present study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
C.H. Rice. The author’s study was supported by ConAgra. DOI: 10.1183/09031936.00050808
L.J. Rubin has served as an investigator and consultant for Actelion, Pfizer, United Therapeutics and Gilead in the development of treatments for pulmonary artery hypertension. DOI: 10.1183/09031936.00107108
M. Rutten-van Mölken is involved in the development and publication of the Dutch population-based life-time COPD model, which is financially supported by the Dutch Ministry of Health through the National Institute of Public Health and the Environment. She has also published a short-term COPD model to assess the cost-effectiveness of bronchodilator treatment in COPD, which was financially supported by Boehringer Ingelheim. She acts as a consultant on COPD modelling for Novartis and Nycomed. DOI: 10.1183/09031936.00108409
P.H. Ryan. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
Å. Ryrfeldt. The author’s study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
S
Back to Top
H.J. Schünemann has received no personal payments from pharmaceutical industry, but in the last three years he has received research grants and/or honoraria that were deposited into research accounts or received by a research group that he belongs to from AstraZeneca (research grant, honoraria), Chiesi Foundation (honorarium), Lily (honorarium), Pfizer (research grant, honorarium), and UnitedBioSource (honorarium) for development or consulting regarding quality of life instruments for chronic respiratory diseases and as lecture fees related to the methodology of evidence based practice guideline development and/or research methodology. Other institutions or organisations that he is affiliated with likely receive funding from for-profit sponsors that are supporting infrastructure and research that may serve his work. DOI: 10.1183/09031936.00095408
S. Semple was supported by a non-commercial grant from Talecris Biotherapeutics who had no involvement in study design or conduct, manuscript preparation or submission. DOI: 10.1183/09031936.00087908
F. Sériès. The author’s study was supported by Abbott Pharmaceutical. DOI: 10.1183/09031936.00167308
H. J. Seyfarth has received lecturer honoraria from Actelion Pharmaceuticals and Bayer/Schering. DOI: 10.1183/09031936.00130408
S. Sharma is an employee of GlaxsoSmithKline. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
P.M. Shirtcliffe. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
M. Shulte is an employee of Inamed Research. The study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
E.K. Silverman has received grant support and consulting fees from GlaxoSmithKline for two studies of COPD genetics. He has received consulting fees from Astra-Zeneca. He has also received honoraria from Wyeth, Bayer, GlaxoSmithKline, and Astra-Zeneca. DOI: 10.1183/09031936.00141808
E.K. Silverman has received grant support and consulting fees from GlaxoSmithKline for two studies of chronic obstructive pulmonary disease genetics. He has received consulting fees from AstraZeneca, and also honoraria from Wyeth, Bayer, GlaxoSmithKline and AstraZeneca. The author’s study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
T. Similowski has received honoraria from Atrotech (Finland) and Synapse Biomedical (USA) to translate from English to French the user's manuals of the two neurostimulator devices used in the patients in this study. DOI: 10.1183/09031936.00177708
M. Singh is an employee of Lionex GmbH. DOI: 10.1183/09031936.00013409
O. Sitbon has relationships with drug companies including Actelion, BayerSchering, GSK, Pfizer and United Therapeutics, in addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00006508
O. Sitbon has received reimbursement for attending symposium and funds for research from Actelion, Pfizer, GSK and Bayer-Schering. He has received fees for speaking from Actelion, Pfizer, GSK, Bayer-Schering and United Therapeutics. He has received fees for consulting from Actelion, Pfizer and GSK. DOI: 10.1183/09031936.00068009
O. Sitbon has, in the past 5 years, received: reimbursement for attending a symposium; a fee for speaking; a fee for organising education; funds for research; funds for a member of staff; fees for consulting. O. Sitbon has relationships with drug companies including Actelion, BayerSchering, GSK, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00102609
F.W.J.M. Smeenk has received educational grants, and consulting and speaker fees from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.50130408
A. Spaar. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. This grant paid for consumables and the salary of A. Spaar. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author’s systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
A. Spaar. The author’s work did not have specific funding, and was done in time made available by the authors’ institutes. However, the study partly used data available from previous work. With relation to this previous work, the Horten Centre received a grant from Kleijnen Systematic Reviews Ltd for conducting systematic reviews in respiratory medicine. This grant paid for consumables and the salaries of B. Bausch and A. Spaar. DOI: 10.1183/09031936.00159108
R.A. Stockley. The authors are supported by a non-commercial grant from Talecris Biotherapeutics who had no involvement in study design or conduct, manuscript preparation or submission. DOI: 10.1183/09031936.00087908
R. Strassmann. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. R. Strassmann did not receive any salary support and performed all work as part of her medical thesis. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author’s systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
V. Strugala is an employee of Technostics Ltd. DOI: 10.1183/09031936.00126908
S. Suissa has participated in advisory board meetings and conferences, and has acted as a speaker in scientific meetings for various companies (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer and Sepracor). The author has also received research grants from AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00190908
B-M. Sundblad. This study was supported by a grant from the Research Department of AFA Insurance Company (Stockholm, Sweden). DOI: 10.1183/09031936.00105308
L. Swedin. The author’s study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
T
Back to Top
R. Tal-Singer is an employee of GlaxoSmithKline, the sponsor of the studies reported in the present manuscript. DOI: 10.1183/09031936.00156508
R.K. Thomas has received research support from AstraZeneca, served as a consultant to Sequenom and received speaker honoraria by 454 Life Sciences and Infinity Pharmaceuticals. DOI: 10.1183/09031936.00042409
A. Torres has received fees for speaking from Astellas and Bayer, funds for research from Pfizer and fees for consulting from Wyeth, Astellas and Bayer. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
A. Torres has received payments for advisory board work from Astellas and Bayer, investigation grant from Pfizer and payment from Astella, Bayer and Sanofi to speak in sponsored symposia. DOI: 10.1183/09031936.00120009
J. Travers. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
J. Travers. The author’s study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
U
Back to Top
V
Back to Top
A. Vacca has acted as an expert witness on the study topic. The present study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
M. van Hage. The author’s study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
M. Venditti has received fee for speaking from Pfizer, GlaxoSmithKline, Novartis, Aventis, Bayer, Angelini, Gilead and Wyeth. DOI: 10.1183/09031936.00007709
J. Vestbo has received fees for speaking from GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Pfizer; and funds for research and for a member of staff, from GlaxoSmithKline. He is a member of an advisory board and expert panel for GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Hoffmann-La Roche. His wife works for AstraZeneca in Copenhagen. He has, in 1985, received 267,000 Dkr from the Scandinavian Tobacco Company in support for a research project on exposure to cement dust, smoking, and respiratory disease. The present study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
J. Vestbo. Research grants to support work carried out in the department in which J. Vestbo works have come from GlaxoSmithKline. J. Vestbo has received honoraria from GlaxoSmithKline, AstraZeneca, Boehringer-Ingeheim and Pfizer for speaking in scientific meetings and for travel to these meetings. J. Vestbo serves on an advisory board and expert panel for GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Hoffmann-La Roche. Finally, his wife, Inge Vestbo, is an employee of AstraZeneca. In 1985 he received 267,000 Dkr from Scandinavian Tobacco Company in support for a research project on exposure to cement dust, smoking, and respiratory disease. DOI: 10.1183/09031936.00122608
S. Vilà. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
W.M. Vollmer has served on ad hoc advisory boards for Merck and Co., has participated in COPD workshops funded by Merck and GlaxoSmithKline, and is director of the Burden of Obstructive Lung Disease (BOLD) operations centre, funding for which includes unrestricted educational grants to the Kaiser Permanente Center for Health Research from Boehringer Ingelheim, Pfizer, Altana, GlaxoSmithKline, AstraZeneca, Novartis, Chiesi and Merck. W.M. Vollmer is a past recipient of funding from Merck, which was associated with the validation work for the ATAQ instrument; however, he receives no royalties or other compensation from the use of ATAQ by others and does not hold any copyright privileges for the ATAQ instrument. DOI: 10.1183/09031936.00164608
A. Vonk-Noordegraaf received a $1,200 lecture fee from Actelion. DOI: 10.1183/09031936.00106008
I. von Scheele. The author’s study was supported by a grant from the Research Department of AFA Insurance Company (Stockholm, Sweden). DOI: 10.1183/09031936.00105308
W
Back to Top
M. Weatherall. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00159708
M. Weatherall. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
K.A. Webb. The author’s study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
M. Wencker is employed by Talecris and holds company shares by Talecris. The study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
K.L. White and others at IHI Environmental were hired by ConAgra to perform the industrial hygiene exposure assessments discussed in the paper. This work occurred between early 2005 and the present. The author’s study was supported by ConAgra. DOI: 10.1183/09031936.00050808
M. Wijesinghe. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00159708
I. Wiklund was employed by GlaxoSmithKline at the time of the study. The study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
M.V. Williams. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
L.R. Willits is employed by and holds shares in GlaxoSmithKline. The author’s study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
J. Winkler has received lecturer honoraria from Actelion Pharmaceuticals and Bayer/Schering. DOI: 10.1183/09031936.00130408
A.M. Wood. The authors are supported by a non-commercial grant from Talecris Biotherapeutics who had no involvement in study design or conduct, manuscript preparation or submission. DOI: 10.1183/09031936.00087908
M. Woodhead has received payment for lecturing from Pfizer and for being a member of a data monitoring committee from Wyeth. DOI: 10.1183/09031936.00120009
E.F.M. Wouters is a member of the scientific advisory boards for GSK, Boehringer Ingelheim, AstraZeneca and Numico, and he has and received lecture fees from GSK, AstraZeneca and Boehringer Ingelheim. The author has also received research grants between 2004 and 2007 from GSK, AstraZeneca, Boehringer Ingelheim, Centocor and Numico. DOI: 10.1183/09031936.50130408
W
Back to Top
Y
Back to Top
J.C. Yates is an employee of and owns shares in GlaxoSmithKline. The author’s study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
Z
Back to Top
G. Zhu is a full-time employee of GlaxoSmithKline. DOI: 10.1183/09031936.00141808
Back to Top
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |